Tags

Type your tag names separated by a space and hit enter

Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
Int J Tuberc Lung Dis. 2018 11 01; 22(11):1344-1349.IJ

Abstract

SETTING

Four New York City (NYC) Health Department tuberculosis (TB) clinics.

OBJECTIVE

To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI).

DESIGN

Retrospective analysis of patients treated for LTBI from January to June 2015. Poisson regression with robust standard error was used to examine the factors associated with treatment completion.

RESULTS

Of the patients on 9H, 49% (27/55) completed treatment compared with 70% (187/269) of patients on 4R (P = 0.003) and 79% (99/125) of patients on 3HP (P < 0.001). When adjusting for age, sex, and TB risk factors, patients on 4R (adjusted risk ratio [aRR] 1.39, 95%CI 1.07-1.81) and 3HP (aRR 1.67, 95%CI 1.27-2.19) were more likely to complete treatment than patients on 9H. Treatment was discontinued due to side effects in 1% (3/269) of patients on 4R, 2% (2/125) of patients on 3HP, and 4% (2/55) of patients on 9H.

CONCLUSIONS

Most patients were placed on shorter regimens for LTBI treatment, and higher treatment completion was observed. Encouraging community providers to use shorter regimens for LTBI treatment would reduce the TB disease burden in NYC.

Authors+Show Affiliations

New York City Department of Health and Mental Hygiene, New York, New York.New York City Department of Health and Mental Hygiene, New York, New York, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.New York City Department of Health and Mental Hygiene, New York, New York, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.New York City Department of Health and Mental Hygiene, New York, New York.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

30355415

Citation

Macaraig, M M., et al. "Improved Treatment Completion With Shorter Treatment Regimens for Latent Tuberculous Infection." The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, vol. 22, no. 11, 2018, pp. 1344-1349.
Macaraig MM, Jalees M, Lam C, et al. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018;22(11):1344-1349.
Macaraig, M. M., Jalees, M., Lam, C., & Burzynski, J. (2018). Improved treatment completion with shorter treatment regimens for latent tuberculous infection. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 22(11), 1344-1349. https://doi.org/10.5588/ijtld.18.0035
Macaraig MM, et al. Improved Treatment Completion With Shorter Treatment Regimens for Latent Tuberculous Infection. Int J Tuberc Lung Dis. 2018 11 1;22(11):1344-1349. PubMed PMID: 30355415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved treatment completion with shorter treatment regimens for latent tuberculous infection. AU - Macaraig,M M, AU - Jalees,M, AU - Lam,C, AU - Burzynski,J, PY - 2018/10/26/entrez PY - 2018/10/26/pubmed PY - 2019/9/17/medline SP - 1344 EP - 1349 JF - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease JO - Int J Tuberc Lung Dis VL - 22 IS - 11 N2 - SETTING: Four New York City (NYC) Health Department tuberculosis (TB) clinics. OBJECTIVE: To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI). DESIGN: Retrospective analysis of patients treated for LTBI from January to June 2015. Poisson regression with robust standard error was used to examine the factors associated with treatment completion. RESULTS: Of the patients on 9H, 49% (27/55) completed treatment compared with 70% (187/269) of patients on 4R (P = 0.003) and 79% (99/125) of patients on 3HP (P < 0.001). When adjusting for age, sex, and TB risk factors, patients on 4R (adjusted risk ratio [aRR] 1.39, 95%CI 1.07-1.81) and 3HP (aRR 1.67, 95%CI 1.27-2.19) were more likely to complete treatment than patients on 9H. Treatment was discontinued due to side effects in 1% (3/269) of patients on 4R, 2% (2/125) of patients on 3HP, and 4% (2/55) of patients on 9H. CONCLUSIONS: Most patients were placed on shorter regimens for LTBI treatment, and higher treatment completion was observed. Encouraging community providers to use shorter regimens for LTBI treatment would reduce the TB disease burden in NYC. SN - 1815-7920 UR - https://www.unboundmedicine.com/medline/citation/30355415/Improved_treatment_completion_with_shorter_treatment_regimens_for_latent_tuberculous_infection_ L2 - https://www.ingentaconnect.com/openurl?genre=article&amp;issn=1027-3719&amp;volume=22&amp;issue=11&amp;spage=1344&amp;aulast=Macaraig DB - PRIME DP - Unbound Medicine ER -